Physician

Douglas D. Heldreth, M.D.

According to 2025 Medicare claims, Douglas Heldreth, M.D. (NPI: 1699766378) practices hematology/oncology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34105-5020.

Heldreth's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,355 traditional Medicare patients, billed 396,099 HCPCS/CPT codes, and received $5,347,711 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,584 prescription claims across 335 beneficiaries totaling $5,275,055 in drug costs, led by Revlimid (Lenalidomide). DME data shows 42 claims. Open Payments data shows 131 records totaling $2,734. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $2,059,387 to $5,275,055. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,579 to $1,485.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,525	397,203	$3,854,353
2016	1,441	395,600	$4,389,721
2017	1,667	333,838	$4,940,963
2018	1,755	367,507	$5,421,372
2019	1,782	482,787	$6,379,519
2020	1,522	411,709	$6,550,537
2021	1,517	411,629	$6,941,175
2022	1,249	406,133	$5,596,629
2023	1,069	317,583	$5,253,910
2024	1,355	396,099	$5,347,711

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	441	2,452	$2,059,387
2016	441	2,332	$2,185,327
2017	426	2,275	$3,175,859
2018	409	2,375	$3,717,999
2019	421	2,304	$4,718,929
2020	400	2,100	$3,817,612
2021	377	1,966	$3,623,053
2022	351	1,783	$3,810,019
2023	299	1,506	$3,775,742
2024	335	1,584	$5,275,055

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	56	264	$67,152
2016	66	277	$70,488
2017	47	189	$36,277
2018	57	157	$13,341
2019	55	158	$10,661
2020	48	153	$7,323
2021	36	160	$9,348
2022	N/R	127	$3,754
2023	22	105	$12,310
2024	N/R	42	$712

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	744	1,611	$99
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	550	843	$13
96372	Injection of drug or substance under skin or into muscle	367	1,400	$11
36415	Insertion of needle into vein for collection of blood sample	1,063	2,921	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,041	2,910	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	44	1,232	$742,249
Imbruvica	Ibrutinib	43	1,218	$585,631
Ibrance	Palbociclib	37	931	$502,626
Pomalyst	Pomalidomide	20	553	$355,265
Verzenio	Abemaciclib	20	560	$308,898

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$498
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	131	$2,734	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Douglas D. Heldreth, M.D.?

Tedicare shows public-source Medicare data for Douglas D. Heldreth, M.D. (NPI 1699766378), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Douglas D. Heldreth, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Douglas D. Heldreth, M.D.?

Douglas D. Heldreth, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Douglas D. Heldreth, M.D. have Open Payments data?

Douglas D. Heldreth, M.D. has 131 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.